Startseite UR

Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study

van den Bent, Martin J. ; Baumert, Brigitta ; Erridge, Sara C. ; Vogelbaum, Michael A. ; Nowak, Anna K. ; Sanson, Marc ; Brandes, Alba Ariela ; Clement, Paul M. ; Baurain, Jean Francais ; Mason, Warren P. ; Wheeler, Helen ; Chinot, Olivier L. ; Gill, Sanjeev ; Griffin, Matthew ; Brachman, David G. ; Taal, Walter ; Rudà, Roberta ; Weller, Michael ; McBain, Catherine ; Reijneveld, Jaap ; Enting, Roelien H. ; Weber, Damien C. ; Lesimple, Thierry ; Clenton, Susan ; Gijtenbeek, Anja ; Pascoe, Sarah ; Herrlinger, Ulrich ; Hau, Peter ; Dhermain, Frederic ; van Heuvel, Irene ; Stupp, Roger ; Aldape, Ken ; Jenkins, Robert B. ; Dubbink, Hendrikus Jan ; Dinjens, Winand N. M. ; Wesseling, Pieter ; Nuyens, Sarah ; Golfinopoulos, Vassilis ; Gorlia, Thierry ; Wick, Wolfgang ; Kros, Johan M.



Zusammenfassung

Background The role of temozolomide chemotherapy in newly diagnosed 1p/19q non-co-deleted anaplastic gliomas, which are associated with lower sensitivity to chemotherapy and worse prognosis than 1p/19q co-deleted tumours, is unclear. We assessed the use of radiotherapy with concurrent and adjuvant temozolomide in adults with non-codeleted anaplastic gliomas. Methods This was a phase 3, ...

plus


Nur für Besitzer und Autoren: Kontrollseite des Eintrags
  1. Universität

Universitätsbibliothek

Publikationsserver

Kontakt:

Publizieren: oa@ur.de
0941 943 -4239 oder -69394

Dissertationen: dissertationen@ur.de
0941 943 -3904

Forschungsdaten: datahub@ur.de
0941 943 -5707

Ansprechpartner